A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome
Latest Information Update: 27 Dec 2022
Price :
$35 *
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms EXAMINE
- Sponsors Takeda; Takeda Global Research and Development Center
- 26 Dec 2022 Results (n=193) assessing External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome published in the Diabetes, Obesity and Metabolism
- 01 Jul 2021 Results assessing the clinical correlates of increased red blood cell distribution width, its potential mechanistic association with multiple circulating biomarkers, and its prognostic value in patients, published in the Diabetes, Obesity and Metabolism
- 01 Sep 2020 Results of a post hoc analysis analysis assessing the impact of timing of enrolment on subsequent CV outcomes, presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology